Compare TransMedics Group Inc (TMDX) vs Vanguard Tax Managed Fund FTSE Developed Markets ETF (VEA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TransMedics Group Inc vs Vanguard Tax Managed Fund FTSE Developed Markets ETF — how do they compare? TransMedics Group Inc trades at $77.87 (market cap $2.74B), while Vanguard Tax Managed Fund FTSE Developed Markets ETF trades at $70.35 (market cap $323.80B). The key difference: Vanguard Tax Managed Fund FTSE Developed Markets ETF is far larger — about 118.2× TransMedics Group Inc's market cap, and Vanguard Tax Managed Fund FTSE Developed Markets ETF is trading nearer its 52-week high, TransMedics Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold TransMedics Group Inc for 24 Days and Vanguard Tax Managed Fund FTSE Developed Markets ETF for 131 Days on average.
| TMDX | VEA | |
|---|---|---|
Market Cap | $2.74B | $323.80B |
Volume | 949,331 | 17,001,112 |
Sector | Health | — |
52-Week High | $150.42 | $73.79 |
52-Week Low | $61.99 | $58.90 |
Typical Hold Time | 24 Days | 131 Days |
Enterprise Value | $3.13B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TransMedics Group (TMDX) trades at $77.87, down 3.95% on the day, amid a bearish technical signal and recent earnings misses. The company maintains strong profitability with a 22.69% net income margin and 36.28% ROE, though 2026 projections show margin compression. Analyst consensus remains bullish with a $99.75 price target, but sentiment is clouded by multiple legal investigations into fiduciary duties announced in late August and September 2026.
The stock faces near-term pressure from technical weakness and legal overhangs, but solid fundamentals and analyst conviction suggest long-term potential if execution improves. Key risks include ongoing legal scrutiny, margin pressures from heavy investment, and volatility around future earnings reports.
VEA trades at $69.86, down 0.57% on the day, with a bearish technical signal from moving averages and oscillators. The ETF's low expense ratio of 0.03% and focus on developed markets outside the U.S. are key attributes, though financial ratios are not disclosed in the provided data. Recent news highlights institutional activity, with firms like Allianz Asset Management increasing positions while others reduced stakes.
The outlook for VEA is mixed, with technical indicators suggesting near-term pressure, but its cost efficiency and dividend yield offer long-term value. Risks include market volatility and economic shifts in developed economies. Investors should weigh the bearish technicals against the fund's structural advantages in a diversified portfolio.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →About Vanguard Tax Managed Fund FTSE Developed Markets ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Developed All Cap ex US Index, a market-capitalization-weighted index that is made up of approximately 4022 common stocks of large-, mid-, and small-cap companies located in Canada and the major markets of Europe and the Pacific region. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.
Read more on VEA →
